This study is to evaluate the clinical value of serum tumor supplied group of factors (TSGF) in diagnosis of canine cancer. 145 dogs with malignant tumors,32 benign diseases,34 dogs with non-tumor diseases,and 6 healt...This study is to evaluate the clinical value of serum tumor supplied group of factors (TSGF) in diagnosis of canine cancer. 145 dogs with malignant tumors,32 benign diseases,34 dogs with non-tumor diseases,and 6 healthy dogs. Biochemical colorimetric assay were used to detect the serum TSGF level. Blood samples were collected at the time of initial diagnostic evaluation,before each chemotherapy session,and at follow-up visits. The serum TSGF level in dogs with malignant tumors,benign diseases,non-tumor diseases and healthy dog were 67. 3 ± 22. 1 U/mL,57. 3 ± 7. 58 U/mL,60. 2 ± 14. 2 U/mL and 54. 6 ± 3. 21 U/mL,the first group was statistically significant higher than the latter (P < 0. 05). 56. 6% malignant patients exceeded the upper limit of the normal reference range (61 U/mL). The samples were classified to groups according clinic stage. The TSGF level from malignant tumor groups were stage I 56. 8 ± 5. 93 U/mL. stage II 66. 7 ± 25. 7 U/mL,stage III 75. 6 ± 22. 7 U/mL and stage IV 73. 9 ± 29. 6 U/mL. Excluding stage I, the TSGF level of all stages are statistically significant higher than healthy group,respectively,the stage III was also statistically significant higher than stage I. Further follow-up study indicated that in entirely insect group,the TSGF level decreased after treatment and kept in low level. In the partly insect group,although the TSGF activity decreased in a short term after surgery,the TSGF level would increase again and kept in high level. From this fact we considered that TSGF level is expected to be a newly potential biomarker in screening neoplastic diseases in veterinary and a monitoring factor for predicting relapse.展开更多
文摘This study is to evaluate the clinical value of serum tumor supplied group of factors (TSGF) in diagnosis of canine cancer. 145 dogs with malignant tumors,32 benign diseases,34 dogs with non-tumor diseases,and 6 healthy dogs. Biochemical colorimetric assay were used to detect the serum TSGF level. Blood samples were collected at the time of initial diagnostic evaluation,before each chemotherapy session,and at follow-up visits. The serum TSGF level in dogs with malignant tumors,benign diseases,non-tumor diseases and healthy dog were 67. 3 ± 22. 1 U/mL,57. 3 ± 7. 58 U/mL,60. 2 ± 14. 2 U/mL and 54. 6 ± 3. 21 U/mL,the first group was statistically significant higher than the latter (P < 0. 05). 56. 6% malignant patients exceeded the upper limit of the normal reference range (61 U/mL). The samples were classified to groups according clinic stage. The TSGF level from malignant tumor groups were stage I 56. 8 ± 5. 93 U/mL. stage II 66. 7 ± 25. 7 U/mL,stage III 75. 6 ± 22. 7 U/mL and stage IV 73. 9 ± 29. 6 U/mL. Excluding stage I, the TSGF level of all stages are statistically significant higher than healthy group,respectively,the stage III was also statistically significant higher than stage I. Further follow-up study indicated that in entirely insect group,the TSGF level decreased after treatment and kept in low level. In the partly insect group,although the TSGF activity decreased in a short term after surgery,the TSGF level would increase again and kept in high level. From this fact we considered that TSGF level is expected to be a newly potential biomarker in screening neoplastic diseases in veterinary and a monitoring factor for predicting relapse.
